Participants will receive one tablet each day for about nine months. Throughout the study they will visit the clinic regularly, where health care staff will collect a urine sample, usually the first morning urine, and perform a simple test that compares the protein level to a normal waste product to see how much protein is present. Blood samples will also be taken to understand how the body absorbs and clears the medication. Doctors will monitor safety by checking for any side effects, routine lab results, and vital signs during the visits.

Participants will receive a single injection of the imaging agent, followed by a series of imaging sessions that combine PET and CT scans to look at the transplanted kidney, nearby lymph nodes, spleen, liver and bone marrow. A small blood sample will also be taken to measure immune cells using a laboratory technique called flow cytometry. The study lasts for a short period of time after the injection, during which the imaging and blood tests are performed to assess the distribution of the agent and the activity of immune cells.

The study is planned in two parts. In the first part, maribavir is taken for about 6 months. If the virus level drops but does not fall enough, treatment may continue for about 3 more months. During the study, the health of the participants and the amount of virus in the body are followed over time, along with whether the virus comes back after treatment is stopped.

Epstein-Barr virus is a common virus that can stay active in the body after infection. In people who have had a kidney transplant, the immune system is weakened to protect the new organ, and this can make it harder to control the virus. Maribavir is an antiviral medicine, which means it is designed to stop a virus from making more copies of itself.

The purpose of the study is to assess how Dazodalibep affects the systemic manifestations, or widespread symptoms, of Sjögren’s Syndrome in participants who have moderate-to-severe disease activity. Participants in the study will receive either Dazodalibep or a placebo over a period of time, and their health will be monitored to observe any changes in their condition. The study will last for several weeks, and participants will undergo regular assessments to track their progress and any side effects they may experience.

Throughout the study, researchers will collect data on various health indicators, such as changes in disease activity scores and other symptoms related to Sjögren’s Syndrome. This information will help determine the potential benefits and risks of using Dazodalibep as a treatment option for this condition. The study is designed to provide valuable insights into the management of Sjögren’s Syndrome and to explore new possibilities for improving the quality of life for those affected by this disease.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

This is an extension study, which means it is designed for people who have already participated in and completed earlier studies of dazodalibep for Sjögren’s Syndrome. Those who join this study will continue to receive dazodalibep treatment for a longer time so that researchers can observe how safe the medication is when used over many months or years. The study will track any unwanted effects that occur during treatment, including any serious health problems that might develop. Researchers will also check if the body develops any immune responses against the medication by looking for anti-drug antibodies, which are proteins the body might make in reaction to the treatment.

Throughout the study, blood samples will be collected to measure the amount of dazodalibep in the bloodstream, which helps researchers understand how the medication moves through and stays in the body. The study is open-label, meaning both the participants and doctors will know that everyone is receiving the active medication rather than placebo. This long-term study allows researchers to gather important information about the ongoing safety of dazodalibep in people with Sjögren’s Syndrome over an extended treatment period.

The purpose of the study is to find out if giving this stem cell treatment through an infusion into the vein can help restore heart function in people who have been recently diagnosed with this type of heart failure. The study will compare how well the heart works in patients who receive the stem cell treatment versus those who receive the placebo. Patients in the study will receive their assigned treatment through infusions and will be followed for twelve months to see how their heart function changes over time.

During the study, doctors will measure various aspects of heart function using different methods. They will check the heart’s pumping ability and the size of the heart chambers at different time points after the treatment. Doctors will also assess how patients feel and function in their daily lives by checking their symptoms, their ability to walk for six minutes, and asking them to complete questionnaires about their quality of life. Blood tests will be performed to measure a substance that indicates heart stress. The study will also carefully monitor any unwanted effects or reactions that patients may experience to ensure the treatment is safe.

During the study, participants will receive either Tenofovir Alafenamide Fumarate or placebo in addition to their regular multiple sclerosis treatment. The medication or placebo will be given as oral capsules over a period of 52 weeks. This is a double-blinded study, which means neither the participants nor the healthcare providers will know who receives the actual medication.

The research aims to determine if this combination treatment approach is more effective at protecting nerve cells compared to standard treatment alone. Throughout the study, various tests will be performed to monitor the participants’ response to treatment, including examination of spinal fluid and brain imaging. The study will also track how well patients tolerate the treatment and monitor any changes in their fatigue levels.

The study involves adults who either have already had their spleen removed or are scheduled for spleen removal surgery. Participants will receive two different vaccines: first Prevenar 20, followed by CAPVAXIVE at least 12 months later. Both vaccines are given as a single injection into the muscle. The main focus is on measuring how well the immune system responds to the vaccines when given at different times relative to spleen removal.

The research team will collect blood samples to measure antibody levels and immune cell responses at various points during the study. This will help determine the best timing for vaccination in patients without a spleen. The study will continue for approximately two years, comparing immune responses between patients vaccinated before spleen removal, after spleen removal, and healthy individuals who still have their spleen.

The study involves taking small samples from lymph nodes and blood to analyze how the immune system responds to vaccination. Participants will receive a single dose of one of the pneumococcal vaccines through an intramuscular injection. The researchers will monitor the immune response for up to 6 months after vaccination by collecting blood samples and small amounts of saliva.

The research aims to understand how factors like age and HIV infection influence the body’s response to different types of vaccines. This knowledge could help improve vaccination strategies for different groups of people. The study will also look at how lifestyle factors such as diet, exercise, and smoking might affect the immune response to vaccination.

The purpose of the study is to assess how well infants’ immune systems respond to the early administration of the measles vaccine, known as MMR-0, when given to children younger than 12 months during a measles outbreak. The study will compare the immune response of infants who receive the MMR-0 vaccine with those who receive the standard measles vaccine, MMR-1, at 14 months of age. The study will monitor the levels of antibodies, which are proteins the body makes to fight infections, in the infants’ blood at different times after vaccination.

Participants in the study will receive the vaccines through an injection into the muscle. The study will track the infants’ immune responses over time, including four weeks after the MMR-0 vaccination and up to one year after the MMR-1 vaccination. The study aims to provide valuable information on the effectiveness and safety of early measles vaccination in young children during an outbreak.

The purpose of the study is to assess the level of antibodies, which are proteins in the blood that help fight infections, against the most common variant of the virus. This will be done three times a year. The study will also look at how well the vaccines work in creating a strong immune response, which includes both the quality of the antibody response and the cellular immune response, which involves other parts of the immune system that help protect against infections.

Participants in the study will receive the vaccines through an injection. The study will take place over several years, from 2023 to 2026, to gather comprehensive data on how the immune system responds over time. This information will help improve understanding of vaccine effectiveness in people with different health conditions and contribute to better protection strategies against COVID-19.

The purpose of the study is to explore how these medications can modify the immune system’s response during inflammation. Participants will receive one of the medications or a placebo, and their immune responses will be monitored. The study will involve repeated exposure to a substance called lipopolysaccharide (LPS), which is used to trigger an inflammatory response in the body. This will help researchers understand how the medications affect the immune system over time.

Throughout the study, participants will undergo various tests and assessments to measure changes in their immune response. These tests will include monitoring levels of certain proteins and substances in the blood that are associated with inflammation. The study aims to provide valuable insights into how these medications can potentially be used to manage inflammatory conditions in the future.

Participants in the study will receive two doses of the Bexsero vaccine. The vaccine is given as an injection into the muscle. The study will last for a total of 56 days, during which participants will have their blood tested to measure the levels of antibodies, which are proteins made by the immune system to fight infections. These tests will help researchers understand how well the vaccine works in different people.

The study will also look at how certain immune cells, called T cells, respond to the vaccine. T cells are a type of white blood cell that play a crucial role in the immune system by helping to protect the body against infections. By comparing the immune responses of transgender and cisgender participants, the study aims to provide valuable insights into how gender and sex may influence the effectiveness of the Bexsero vaccine.

The purpose of the study is to evaluate how the body’s natural defense system, known as the innate immune response, reacts shortly after receiving the Comirnaty JN.1 vaccine. Participants will receive the vaccine through an injection into the muscle. The study will observe the body’s response at different times: before the vaccine is given, and then 6 hours and 24 hours after the injection. Researchers will look at certain markers in the blood that indicate how the immune system is responding.

Throughout the study, researchers will also monitor for any serious side effects that might be related to the vaccine. The study aims to provide more information on how the vaccine affects the immune system in the short term, which can help in understanding its overall effectiveness and safety. The study is expected to conclude by February 2025.

The purpose of the study is to assess how the timing of the Tdap vaccine (which stands for tetanus, diphtheria, and acellular pertussis) during pregnancy influences the immune responses in pregnant women. This includes looking at the levels of antibodies, which are proteins in the blood that help fight infections, in the mother’s blood at different times: before the vaccine, after the vaccine, at the time of delivery, and six months after giving birth. The study will also measure the levels of antibodies in the baby’s blood at birth to understand how well these protective proteins are passed from the mother to the baby through the placenta.

Participants in the study will receive the Tdap vaccine during their pregnancy. The study will involve several visits to monitor the immune responses, including blood tests to measure antibody levels and other immune markers. The study will also look at the presence of antibodies in breast milk six months after giving birth to see how the vaccine timing affects the baby’s protection after birth. This research will help determine the best time to vaccinate pregnant women to provide the most protection for both the mother and the baby.

The purpose of the study is to see how well the vaccine works when given in these different ways and doses. Participants will receive the vaccine and then have their blood tested to measure the levels of antibodies, which are proteins the body makes to fight infections. These tests will be done 28 days after vaccination to see how the body responds. The study will also look at any side effects that participants might experience after getting the vaccine, such as reactions at the injection site or other symptoms.

This study is important for understanding how to best protect older adults from COVID-19, especially since they are at higher risk for severe illness. By comparing different methods and doses of vaccination, researchers hope to find the most effective way to boost immunity in this age group. Participants will be monitored closely throughout the study to ensure their safety and to gather valuable information about the vaccine’s effects.

The purpose of the study is to evaluate the safety and immune response of different dosing schedules of the Gardasil 9 vaccine. The study compares a 2-dose regimen given to boys and girls aged 9 to 14 years with a standard 3-dose regimen given to young women aged 16 to 26 years. The study also looks at the immune response in boys and girls aged 10 to 15 years who have already received one dose of the vaccine at least a year before joining the study. Participants will receive the vaccine at different intervals, and their immune response will be measured to see how well the vaccine works over time.

Throughout the study, participants will be monitored for any side effects or adverse reactions to the vaccine. The study aims to ensure that the vaccine is safe and effective in preventing HPV-related diseases. Participants will receive the vaccine through an intramuscular injection, which means the shot is given directly into a muscle. The study will help determine the best dosing schedule for the Gardasil 9 vaccine to provide optimal protection against HPV.

The purpose of the study is to understand how the immune system, particularly the lymph nodes, responds to these vaccines. Lymph nodes are small glands that play a crucial role in the body’s defense against infections. The study will look at the timing of the peak response of certain immune cells, known as B cells, in the lymph nodes after vaccination. It will also examine other immune cells, such as T cells, and various markers that indicate how the immune system is reacting.

Participants in the study will receive one of the vaccines and will have samples taken from their lymph nodes and blood at different times. These samples will help researchers understand the changes in immune cells and the levels of cytokines, which are substances that help regulate the immune response. The study aims to provide insights into how well the vaccines work in stimulating the immune system to protect against pneumococcal disease.

The purpose of the study is to compare the effectiveness of this new treatment with the standard care currently used for kidney transplant patients. Participants in the study will be divided into three groups, with some receiving the MIC treatment and others receiving the standard care. The study will monitor how well the new treatment helps the body accept the new kidney without causing rejection or other complications.

Throughout the study, participants will be closely observed for any side effects or reactions to the treatment. The study will also track the overall health of the kidney transplant, including any signs of rejection or infection, and the general well-being of the participants. The goal is to determine if the MIC treatment can provide a better outcome for kidney transplant patients compared to the current standard treatments.

The purpose of this study is to understand how the Qdenga vaccine affects the levels of certain antibodies in the blood. Antibodies are proteins made by the immune system to help fight infections. Specifically, the study will look at whether the vaccine causes increased levels of antibodies that might react with other viruses similar to dengue, such as the viruses that cause tick-borne encephalitis (TBEV), yellow fever (YFV), Zika (ZIKV), and Japanese encephalitis (JE). This will be assessed by comparing antibody levels before and 90 days after receiving two doses of the vaccine.

Participants in the study will receive two doses of the Qdenga vaccine. The study will monitor the participants over a period to observe any changes in antibody levels. This research aims to provide valuable information on how the vaccine interacts with the immune system, particularly in people who may travel to areas where dengue fever is common. The study is expected to continue until 2027.

The purpose of the study is to assess how well MK-1654 can prevent RSV-associated medically attended lower respiratory infections in both pre-term and full-term infants. The study will involve monitoring the infants from the time they receive the treatment up to 150 days afterward. During this period, researchers will observe the infants for any signs of RSV-related infections and any side effects that may occur.

Participants in the study will include healthy infants who are either early or moderate pre-term (born between 29 to 34 weeks and 6 days of gestational age) or late pre-term or full-term (born at 35 weeks or later). The study will also track any adverse events, such as fever or rash, to ensure the safety of the treatment. The ultimate goal is to determine if MK-1654 can effectively reduce the incidence of RSV-related infections in infants, providing a potential new option for preventing this common and sometimes serious virus.

The medications involved in this study include Tacrolimus, Azathioprine, Sirolimus, Belatacept, Mycophenolic Acid, Ciclosporin, Everolimus, Mycophenolate Mofetil, and Prednisolone. These medications are commonly used to suppress the immune system and prevent the body from rejecting a transplanted kidney. The study will monitor the time it takes for the virus levels to drop to a safe level, as well as other factors such as kidney function, any episodes of the body rejecting the kidney, and the presence of antibodies that might attack the transplanted organ.

Participants in the study will be randomly assigned to one of the two groups and will be monitored over a period of nine months. The study will track various health indicators, including kidney function and the presence of the virus in the blood, to determine the best approach to managing immunosuppression in these patients. The study aims to provide valuable information on how to best protect kidney transplant recipients from complications related to BK Polyomavirus while maintaining the health of the transplanted kidney.

The purpose of the study is to observe the long-term outcomes in patients who have received a kidney transplant and are considered to be at low risk for immune system complications. These patients are being treated with a medication called tacrolimus, either alone or in combination with another drug called mycophenolate mofetil. The study will compare the survival of the transplanted kidney and the overall health of the patients under these different treatment plans.

Participants in the study will receive the Pneumovax 23 vaccine and their response to the vaccine will be measured at various points over several years. This includes checking the levels of antibodies, which are proteins made by the immune system to fight infections, at 3 and 5 years after the initial vaccination, and again after a booster shot given 5 years later. The study will also monitor other health aspects such as kidney function, patient survival, and any episodes of rejection or infections. This research aims to provide valuable information on how well the vaccine works in kidney transplant patients and how it might affect their long-term health.

Participants in this study will receive tegoprubart through an intravenous (IV) infusion, which means it will be given directly into a vein. The study will monitor participants over a long period to check for any side effects and to see how well the kidney is functioning. The study will also compare the results with those of other treatments to ensure the best possible outcomes for kidney transplant recipients.

Throughout the study, researchers will keep track of any health changes, including side effects and how well the kidney is working. This will help determine the safety and effectiveness of tegoprubart in the long term. The study aims to provide valuable information that could improve the care and treatment of people who have received a kidney transplant.

The purpose of the study is to compare two different ways of giving Ravulizumab to adults with PNH. One group will receive the standard dose, while the other group will receive a personalized dose tailored to their needs. The study aims to see how effective the personalized dosing is compared to the standard dosing. Participants will be monitored for changes in their symptoms and overall health during the study.

Throughout the study, researchers will look at various factors, such as the level of a substance called LDH in the blood, which can indicate how well the treatment is working. They will also assess the quality of life of participants and how often they need blood transfusions. The study will help determine if personalized dosing of Ravulizumab can provide better outcomes for people with PNH.

Participants in the study will receive either the RESCAP iv treatment or a placebo, which looks the same but does not contain the active substance. The study will monitor how quickly patients reach stability in the intensive care unit (ICU) and whether the treatment can reduce the occurrence and severity of acute kidney injury after surgery. Acute kidney injury is a condition where the kidneys suddenly stop working properly, and it can be measured by changes in blood tests and urine output.

The study will follow patients for up to 90 days after their surgery to assess the effects of the treatment. The goal is to determine if RESCAP iv can improve recovery and reduce the risk of complications associated with heart surgery. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effectiveness.

The study involves several medications used to suppress the immune system and prevent rejection of the transplanted kidney. These include Prednisone, a type of steroid taken orally; Basiliximab, also known as CHI-621, which is given through an intravenous injection; Tacrolimus, taken as a capsule; Mycophenolate Mofetil, also in capsule form; and Methylprednisolone, administered as an injection. Another medication used is Rabbit Anti-Human Thymocyte Immunoglobulin, which is given through an infusion. Some participants may receive a placebo instead of one of these medications.

Participants in the study will be randomly assigned to receive either the standard treatment or a personalized treatment plan based on their immunological risk, as determined by the biomarkers. The study will follow participants for two years to monitor outcomes such as kidney function, rejection episodes, and the development of antibodies. The study will also track other health aspects, including infections, metabolic disorders like diabetes, and any serious side effects related to the treatment. The aim is to improve the long-term success of kidney transplants by using a more individualized approach to immunosuppressive therapy.

Participants in the study will receive Axatilimab at one of three doses: 0.3 mg/kg every two weeks, 1 mg/kg every two weeks, or 3 mg/kg every four weeks. The study will observe how well the treatment works and monitor any side effects. The goal is to see if Axatilimab can help reduce the symptoms of cGVHD and improve the quality of life for those affected by this condition.

The study will take place over a period of time, with regular check-ups and assessments to track the participants’ progress. This includes monitoring vital signs, conducting physical examinations, and evaluating the response to the treatment. The information gathered from this study will help determine the potential benefits of Axatilimab for patients with cGVHD who have limited treatment options.

The study aims to find out if this combination can help the body tolerate the new liver, reducing the risk of the immune system attacking it, a condition known as liver allograft rejection. Participants in the study will receive the treatment and be monitored over a period of time to see if they can remain free from the usual medications that suppress the immune system. Some participants will receive a placebo instead of the active treatment to compare the results.

The study will last for up to 60 months, during which participants will undergo regular check-ups and tests to monitor their health and the function of the transplanted liver. The researchers will look at various outcomes, such as the number of patients who can stop taking immunosuppressive drugs and the occurrence of any complications like acute rejection of the liver. The ultimate aim is to improve the quality of life for liver transplant recipients by potentially reducing their dependence on long-term medication.

The purpose of this study is to monitor the safety and tolerability of the TX200-TR101 infusion over a long period. This means researchers will be looking at how well patients tolerate the treatment and whether there are any serious side effects. The study will also track the overall health and survival of the participants, as well as any instances of the transplanted kidney being rejected or not functioning properly.

Participants in this study are individuals who have previously received a kidney transplant and participated in an earlier phase of the study. The study will continue to follow these patients to gather more information about the long-term effects of the treatment. This research aims to provide valuable insights into the potential benefits and risks of using TX200-TR101 for managing kidney transplant rejection.

The purpose of the study is to determine if Anifrolumab can provide a moderate improvement in disease activity over a period of 52 weeks. Participants will receive either Anifrolumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will follow a double-blind method, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will continue their usual treatments for Polymyositis or Dermatomyositis, and their progress will be monitored to assess any changes in their condition. The trial aims to provide valuable information on whether Anifrolumab can be a beneficial addition to the current standard of care for these conditions.

The purpose of the study is to determine if adding Rituximab to a limited period of another treatment called IVIg (intravenous immunoglobulin) can lead to long-term remission of CIDP. Remission means that the symptoms of the disease are reduced or disappear for a period of time. The study aims to see if this combination can help patients stop needing regular IVIg infusions, which can be inconvenient and costly.

Participants in the study will receive Rituximab and will be monitored over a period of time to see if they achieve remission at 52 weeks after starting the treatment. The study will also check if the treatment remains effective at 104 weeks. The goal is to find out if Rituximab can help patients with CIDP maintain stability without needing additional treatments. The study is expected to continue until 2028.

The study tests whether adding itolizumab to corticosteroid treatment works better than adding placebo to corticosteroids for patients with Acute Graft Versus Host Disease. The medication is given through an intravenous infusion (delivered directly into a vein) over a period of 84 days. The total amount of medication given depends on the patient’s weight.

During the study, participants receive either itolizumab (given as EQ001 solution for infusion) or a matching placebo along with corticosteroid treatment. The study uses specific methods to ensure neither the doctors nor the patients know which treatment each person receives. The main goal is to see how well patients respond to the treatment, particularly in the early stages of the disease.

Participants in the study will receive either secukinumab or a placebo, along with a standard treatment involving a medication called glucocorticoid, which helps reduce inflammation. The study will follow participants over a period to monitor their health and any changes in their condition. The main goal is to determine how long it takes for symptoms of GCA to return, if they do, while also assessing the overall health and quality of life of the participants.

Throughout the study, researchers will keep track of any side effects and how well participants tolerate the treatment. The study aims to provide valuable information on whether secukinumab can be a beneficial treatment option for people with GCA, potentially offering a new way to manage this condition and improve patient outcomes.

The treatment involves collecting immune cells from the patient’s blood, modifying them in a laboratory to create QEL-001, and then returning them to the patient through intravenous injection. This is a type of personalized cell therapy where each treatment is specifically made for each individual patient using their own cells. The study will test a single dose of QEL-001 to determine if it is safe and well-tolerated by patients.

The study is designed for patients who received their liver transplant between 1 and 5 years ago from donors with specific tissue characteristics. The main purpose is to evaluate whether this treatment is safe and if it might allow patients to reduce or stop taking their regular anti-rejection medications. Patients will be monitored closely for any side effects and to see how well the treatment works in preventing rejection of the transplanted liver.

The purpose of the study is to understand how tiny particles called *extracellular vesicles* change over time when patients receive *CAR-T cell therapy*. These vesicles are small structures released by cells that can carry signals and materials between cells. The study will also look at a condition called *Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)*, which can occur during this type of treatment. ICANS is a temporary condition that affects the nervous system and can cause symptoms like confusion or difficulty speaking.

Participants in the study will receive *CAR-T cell therapy* and will be monitored over time to see how their *extracellular vesicles* change before and after treatment. The study will also examine how these changes relate to the presence of *ICANS* and other factors like cytokine levels, which are proteins that help control the immune system. Additionally, the study will explore the relationship between these vesicles and any neurological symptoms or sleep apnea that may occur. Imaging tests, such as *MRI*, will be used to observe any changes in the brain before and after treatment. The study aims to provide a better understanding of how *CAR-T cell therapy* affects the body and to improve the management of side effects like *ICANS*.

The purpose of the study is to determine the effectiveness and safety of imlifidase in enabling kidney transplants for these patients. Participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will follow patients for one year after their transplant to monitor their health and the success of the transplant.

Throughout the study, researchers will assess various health indicators, such as kidney function and patient survival, to understand the impact of imlifidase. The study will also compare results with other groups of patients who have received kidney transplants without this treatment. This research aims to provide valuable insights into improving transplant outcomes for patients with high antibody levels.

The purpose of this study is to investigate how safe the Shingrix vaccine is for people with these conditions and how it affects their disease activity. Participants in the study will receive the vaccine and be monitored over a period of time to see if there are any changes in their Psoriasis or Psoriatic Arthritis symptoms. The study will also look at how well the immune system responds to the vaccine by measuring certain immune markers in the blood.

Throughout the study, participants will receive two doses of the Shingrix vaccine, given as an injection into the muscle. They will be observed for any side effects, such as reactions at the injection site or other health changes. The study will last for about a year, with regular check-ups to ensure the safety and effectiveness of the vaccine. Participants will also be checked for any signs of shingles or related complications during the study period.

The purpose of this research is to evaluate how well two different anti-inflammatory medications work compared to artificial tears in managing secretions in patients with eye prostheses. The medications being tested are steroids that help reduce inflammation when applied directly to the eye area. The treatment involves using eye drops for a period of 14 days.

During the study, participants will receive one of the three eye drop solutions. The study will monitor changes in the amount, color, and consistency of eye secretions, as well as the level of inflammation in the eye socket tissue. The research will also track how these treatments affect the daily comfort and quality of life of people who wear artificial eyes.